What is the difference between ABATACEPT and TOCILIZUMAB?

ABATACEPT is a Other and TOCILIZUMAB is a IL-6 Receptor Inhibitor. They reach a similar treatment goal through different pharmacological mechanisms, which is why one may be tolerated by a patient who could not tolerate the other.

Can ABATACEPT and TOCILIZUMAB be used for the same conditions?

Both medications are prescribed for overlapping indications including in combination with a calcineurin inhibitor and methotrexate and biologic disease-modifying antirheumatic drugs (bDMARDS). Always verify with your prescriber and the current FDA label before switching.

Is ORENCIA the same as Tofidence?

No. ORENCIA (ABATACEPT) and Tofidence (TOCILIZUMAB) are distinct medications. They are sometimes confused because of similar branding or because they treat overlapping conditions, but they have different active ingredients and different safety profiles.

Which has fewer side effects, ABATACEPT or TOCILIZUMAB?

Side-effect frequency varies by individual. The side-effect comparison section on this page shows FAERS-reported events for each drug side by side. FAERS is voluntary reporting, so it reflects what patients and clinicians chose to report, not absolute population risk.

Can I switch from ABATACEPT to TOCILIZUMAB?

Switching medications should always be done under prescriber supervision. The "patient stories" section on this page includes accounts from people who have made the switch and what their transition felt like, but those are individual experiences, not protocols.

ABATACEPT vs TOCILIZUMAB

Compare ABATACEPT (ORENCIA) and TOCILIZUMAB (Tofidence) — clinical data, side effects, and patient experiences.

ABATACEPT

ORENCIA · Other

How it works

12.1 Mechanism of Action Abatacept, a selective costimulation modulator, inhibits T-cell (T lymphocyte) activation by binding to CD80 and CD86, thereby blocking interaction with CD...

Approved for

in combination with a calcineurin inhibitor and methotrexate

biologic disease-modifying antirheumatic drugs (bDMARDS)

Janus kinase (JAK) inhibitors] is not recommended. ( 1.5

in combination with a calcineurin inhibitor and methotrexate

Intravenous, SubcutaneousTablet

TOCILIZUMAB

Tofidence, Actemra · IL-6 Receptor Inhibitor

How it works

12.1 Mechanism of Action Tocilizumab products bind to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R), and have been shown to inhibit IL-6-mediated signaling thr...

Approved for

non-invasive or invasive mechanical ventilation

or extracorporeal membrane oxygenation (ECMO).

IntravenousTablet

Quick Comparison

ABATACEPTTOCILIZUMAB

Drug Class

Other

IL-6 Receptor Inhibitor

Route

Intravenous, Subcutaneous

Intravenous

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

ABATACEPT

Drug Not Working

>10%

Joint Pain

1-10%

Fatigue

1-10%

Rash

1-10%

Hair Loss

0.1-1%

TOCILIZUMAB

Drug Not Working

>10%

Joint Pain

1-10%

Fatigue

1-10%

Rash

1-10%

Hair Loss

0.1-1%

FDA Warnings

ABATACEPT

5 WARNINGS AND PRECAUTIONS • Concomitant use with a TNF antagonist can increase the risk of infections and serious infections
2) • Serious infections reported
Discontinue if a serious infection develops
1 Increased Risk of Infection with Concomitant Use of TNF Antagonists, Other Biologic RA/PsA Therapy, or JAK Inhibitors In controlled clinical trials in patients with adult RA, patients receiving concomitant intravenous ORENCIA and TNF antagonist therapy experienced more infections (63% vs

TOCILIZUMAB

5 WARNINGS AND PRECAUTIONS Serious Infections – do not administer TOFIDENCE during an active infection, including localized infections
If a serious infection develops, interrupt TOFIDENCE until the infection is controlled
1 ) Gastrointestinal (GI) perforation—use with caution in patients who may be at increased risk
4 ) Hypersensitivity reactions, including anaphylaxis and death and serious cutaneous reactions including Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) – discontinue TOFIDENCE, treat promptly, and monitor until reaction resolves ( 5

Clinical Trial Data

No head-to-head clinical studies found for ABATACEPT vs TOCILIZUMAB.

ABATACEPT vs TOCILIZUMAB: What You Should Know

Key Differences

ABATACEPT is a Other, while TOCILIZUMAB belongs to the IL-6 Receptor Inhibitor class. This means they work through different pharmacological mechanisms, which may influence both efficacy and side effect profiles. ABATACEPT is administered via Intravenous or Subcutaneous, whereas TOCILIZUMAB uses Intravenous. Route of administration can affect onset of action and patient adherence.

Safety Considerations

ABATACEPT carries 4 FDA warnings. TOCILIZUMAB carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

ADALIMUMAB vs TOCILIZUMAB→ABATACEPT vs ADALIMUMAB→LEFLUNOMIDE vs TOCILIZUMAB→METHOTREXATE vs TOCILIZUMAB→TOCILIZUMAB vs UPADACITINIB→ABATACEPT vs LEFLUNOMIDE→

Primary sources

Every figure on this comparison links back to its primary source. See data sources and methodology for the full provenance trail.

ABATACEPT: DailyMed label · FAERS adverse events · ClinicalTrials.gov
TOCILIZUMAB: DailyMed label · FAERS adverse events · ClinicalTrials.gov

Loading comparison data...

ABATACEPT vs TOCILIZUMAB

Compare ABATACEPT (ORENCIA) and TOCILIZUMAB (Tofidence) — clinical data, side effects, and patient experiences.

ABATACEPT

ORENCIA · Other

How it works

12.1 Mechanism of Action Abatacept, a selective costimulation modulator, inhibits T-cell (T lymphocyte) activation by binding to CD80 and CD86, thereby blocking interaction with CD...

Approved for

in combination with a calcineurin inhibitor and methotrexate

biologic disease-modifying antirheumatic drugs (bDMARDS)

Janus kinase (JAK) inhibitors] is not recommended. ( 1.5

in combination with a calcineurin inhibitor and methotrexate

Intravenous, SubcutaneousTablet

TOCILIZUMAB

Tofidence, Actemra · IL-6 Receptor Inhibitor

How it works

12.1 Mechanism of Action Tocilizumab products bind to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R), and have been shown to inhibit IL-6-mediated signaling thr...

Approved for

non-invasive or invasive mechanical ventilation

or extracorporeal membrane oxygenation (ECMO).

IntravenousTablet

Quick Comparison

ABATACEPTTOCILIZUMAB

Drug Class

Other

IL-6 Receptor Inhibitor

Route

Intravenous, Subcutaneous

Intravenous

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

ABATACEPT

Drug Not Working

>10%

Joint Pain

1-10%

Fatigue

1-10%

Rash

1-10%

Hair Loss

0.1-1%

TOCILIZUMAB

Drug Not Working

>10%

Joint Pain

1-10%

Fatigue

1-10%

Rash

1-10%

Hair Loss

0.1-1%

FDA Warnings

ABATACEPT

5 WARNINGS AND PRECAUTIONS • Concomitant use with a TNF antagonist can increase the risk of infections and serious infections
2) • Serious infections reported
Discontinue if a serious infection develops
1 Increased Risk of Infection with Concomitant Use of TNF Antagonists, Other Biologic RA/PsA Therapy, or JAK Inhibitors In controlled clinical trials in patients with adult RA, patients receiving concomitant intravenous ORENCIA and TNF antagonist therapy experienced more infections (63% vs

TOCILIZUMAB

5 WARNINGS AND PRECAUTIONS Serious Infections – do not administer TOFIDENCE during an active infection, including localized infections
If a serious infection develops, interrupt TOFIDENCE until the infection is controlled
1 ) Gastrointestinal (GI) perforation—use with caution in patients who may be at increased risk
4 ) Hypersensitivity reactions, including anaphylaxis and death and serious cutaneous reactions including Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) – discontinue TOFIDENCE, treat promptly, and monitor until reaction resolves ( 5

Clinical Trial Data

No head-to-head clinical studies found for ABATACEPT vs TOCILIZUMAB.

ABATACEPT vs TOCILIZUMAB: What You Should Know

Key Differences

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.